A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden
(2010) In Scandinavian Journal of Urology and Nephrology 44(3). p.138-146- Abstract
- Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6... (More)
- Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6 months. Results. In total, 235 patients (211 women and 24 men), with a mean age of 61 years (30-87), were recruited. The numbers of patients who completed the OAB-q were 220 and 169 at 3 and 6 months, respectively. The mean reductions in the symptom bother score from baseline were 19.6 and 19.3 at 3 and 6 months, respectively. Significant improvement (p <0.0001) was seen in all HRQoL subscale scores. The proportion of responders who met the minimally important difference (change in the score of 10 or more units between baseline and 6 months) was 64% for the symptom bother score and 34-60% for the total HRQoL and subscale scores. Conclusions. OAB patients beginning treatment with tolterodine ER reported clinically significant improvement in OAB symptoms and self-perceived HRQoL over the 6 months of this observational study. The rate of discontinuation from treatment was 49%. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1618129
- author
- Peeker, Ralph ; Samsioe, Göran LU ; Kowalski, Jan ; Andersson, Ann-Sofie and Bergqvist, Agneta
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- OAB-q, Antimuscarinic, health-related quality of life, overactive, bladder, tolterodine
- in
- Scandinavian Journal of Urology and Nephrology
- volume
- 44
- issue
- 3
- pages
- 138 - 146
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000277391100002
- scopus:77954881755
- pmid:20367449
- ISSN
- 0036-5599
- DOI
- 10.3109/00365591003709468
- language
- English
- LU publication?
- yes
- id
- 375757f9-5560-44a4-b11b-5e9fc798caca (old id 1618129)
- date added to LUP
- 2016-04-01 13:41:04
- date last changed
- 2022-03-06 07:06:25
@article{375757f9-5560-44a4-b11b-5e9fc798caca, abstract = {{Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6 months. Results. In total, 235 patients (211 women and 24 men), with a mean age of 61 years (30-87), were recruited. The numbers of patients who completed the OAB-q were 220 and 169 at 3 and 6 months, respectively. The mean reductions in the symptom bother score from baseline were 19.6 and 19.3 at 3 and 6 months, respectively. Significant improvement (p <0.0001) was seen in all HRQoL subscale scores. The proportion of responders who met the minimally important difference (change in the score of 10 or more units between baseline and 6 months) was 64% for the symptom bother score and 34-60% for the total HRQoL and subscale scores. Conclusions. OAB patients beginning treatment with tolterodine ER reported clinically significant improvement in OAB symptoms and self-perceived HRQoL over the 6 months of this observational study. The rate of discontinuation from treatment was 49%.}}, author = {{Peeker, Ralph and Samsioe, Göran and Kowalski, Jan and Andersson, Ann-Sofie and Bergqvist, Agneta}}, issn = {{0036-5599}}, keywords = {{OAB-q; Antimuscarinic; health-related quality of life; overactive; bladder; tolterodine}}, language = {{eng}}, number = {{3}}, pages = {{138--146}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Journal of Urology and Nephrology}}, title = {{A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden}}, url = {{http://dx.doi.org/10.3109/00365591003709468}}, doi = {{10.3109/00365591003709468}}, volume = {{44}}, year = {{2010}}, }